Pharmacopsychiatry 2013; 46(07): 267-273
DOI: 10.1055/s-0033-1354406
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Inhibition of Olanzapine-Induced Weight Gain by the Retinoid Analog AM-80

M. Richards
1   Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles (UCLA), Los Angeles, United States
,
S. Chiba
2   National Institute of Neuroscience, National Center of Neurology and Psychiatry, Department of Mental Disorder Research, Kodaira, Japan
,
M. Ninomiya
2   National Institute of Neuroscience, National Center of Neurology and Psychiatry, Department of Mental Disorder Research, Kodaira, Japan
,
C. Wakabayasi
2   National Institute of Neuroscience, National Center of Neurology and Psychiatry, Department of Mental Disorder Research, Kodaira, Japan
,
H. Kunugi
2   National Institute of Neuroscience, National Center of Neurology and Psychiatry, Department of Mental Disorder Research, Kodaira, Japan
› Author Affiliations
Further Information

Publication History

received 24 April 2013
revised 07 August 2013

accepted 09 August 2013

Publication Date:
08 October 2013 (online)

Abstract

Introduction:

Weight gain and metabolic abnormalities are common side effects of antipsychotic treatment. Retinoids have been suggested as promising substances to suppress obesity. This study has investigated the effects of a retinoid agonist AM-80 on olanzapine-induced weight gain and metabolic changes in rats.

Methods:

Female Sprague-Dawley rats (7 weeks) were treated with AM-80 (1 mg/kg/day, subcutaneously) and/or olanzapine (4 mg/kg/day, intraperitoneally) for 21 days. Body weight and food/water intake were measured daily. The open field (OFT) and prepulse inhibition (PPI) tests were done on days 18 and 21, respectively. Animals were sacrificed on day 22 to measure weight of adipose tissues and serum levels of adiponectin and leptin levels.

Results:

Olanzapine significantly increased body weight, food/water intake and the mass of inguinal adipose tissue (IAT) compared to vehicle-treated rats. AM-80 demonstrated significant inhibition of weight gain. No significant effect of olanzapine or AM-80 was found on behaviors or serum adiponectin/leptin levels.

Conclusion:

These findings suggests that AM-80 is a potential therapeutic agent to attenuate weight gain and metabolic side effects associated with olanzapine.

Supplementary information

 
  • References

  • 1 Freedman R. Schizophrenia. N Engl J Med 2003; 349: 1738-1749
  • 2 Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696
  • 3 Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?. CNS Drugs 2002; 16: 77-89
  • 4 Zimmermann U, Kraus T, Himmerich H et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193-220
  • 5 Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21: 515-523
  • 6 Goudie AJ, Cooper GD, Halford JC. Antipsychotic-induced weight gain. Diabetes Obes Metab 2005; 7: 478-487
  • 7 Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57-73
  • 8 Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 (Suppl. 10) 55-62
  • 9 Hale AS. Olanzapine. Br J Hosp Med 1997; 58: 442-445
  • 10 Green B. Focus on olanzapine. Curr Med Res Opin 1999; 15: 79-85
  • 11 Wirshing DA, Wirshing WC, Kysar L et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363
  • 12 Graham KA, Perkins DO, Edwards LJ et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162: 118-123
  • 13 Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157: 975-981
  • 14 Baptista T, Contreras Q, Teneud L et al. Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 187-198
  • 15 Baptista T, Araujo de Baptista E, Ying Kin NM et al. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 2002; 957: 144-151
  • 16 Goudie AJ, Smith JA, Halford JC. Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol 2002; 16: 291-296
  • 17 Kaur G, Kulkarni SK. Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 277-285
  • 18 Arjona AA, Zhang SX, Adamson B et al. An animal model of antipsychotic-induced weight gain. Behav Brain Res 2004; 152: 121-127
  • 19 Kirk SL, Neill JC, Jones DN et al. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol 2004; 505: 253-254
  • 20 Cooper GD, Pickavance LC, Wilding JP et al. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 2005; 181: 80-89
  • 21 Berry DC, Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor beta/delta and retinoic acid receptor. Mol Cell Biol 2009; 29: 3286-3296
  • 22 Miwako I, Kagechika H. Tamibarotene. Drugs Today (Barc) 2007; 43: 563-568
  • 23 Takeuchi M. Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia. Gan To Kagaku Ryoho 2006; 33: 397-401
  • 24 Kamei Y, Kawada T, Mizukami J et al. The prevention of adipose differentiation of 3T3-L1 cells caused by retinoic acid is elicited through retinoic acid receptor alpha. Life Sci 1994; 55: PL307-PL312
  • 25 Fell MJ, Marshall KM, Williams J et al. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 2004; 18: 149-155
  • 26 Fatemi SH, Reutiman TJ, Folsom TD et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology 2006; 31: 1888-1899
  • 27 Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology (Berl) 1995; 122: 198-201
  • 28 Depoortere R, Perrault G, Sanger DJ. Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain. Behav Pharmacol 1997; 8: 64-72
  • 29 Yamada S, Harano M, Annoh N et al. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry 1999; 46: 832-838
  • 30 Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 1995; 283: 55-62
  • 31 El-Mallakh RS, Decker S, Morris M et al. Efficacy of olanzapine and haloperidol in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1261-1264
  • 32 Chiba S, Numakawa T, Ninomiya M et al. Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 112-119
  • 33 Wakabayashi C, Numakawa T, Ninomiya M et al. Behavioral and molecular evidence for psychotropic effects in L-theanine. Psychopharmacology (Berl) 2012; 219: 1099-1109
  • 34 Daniels SR. Abnormal weight gain and weight management: are carbohydrates the enemy?. J Pediatr 2003; 142: 225-227
  • 35 Moore NA, Leander JD, Benvenga MJ et al. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 1997; 58 (Suppl. 10) 37-44
  • 36 Pouzet B, Mow T, Kreilgaard M et al. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 2003; 75: 133-140
  • 37 Basson BR, Kinon BJ, Taylor CC et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62: 231-238
  • 38 Baptista T, Zarate J, Joober R et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004; 5: 279-299
  • 39 Haupt DW, Luber A, Maeda J et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005; 30: 184-191
  • 40 Richards AA, Hickman IJ, Wang AY et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol 2006; 26: 232-237
  • 41 Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312-314
  • 42 Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-749
  • 43 Atmaca M, Kuloglu M, Tezcan E et al. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 2003; 60: 99-100
  • 44 McIntyre RS. Antipsychotic drugs and diabetes. CMAJ 2003; 168: 673
  • 45 Cooper GD, Pickavance LC, Wilding JP et al. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 2007; 21: 405-413
  • 46 Fell MJ, Anjum N, Dickinson K et al. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) 2007; 194: 221-231
  • 47 Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 137-145
  • 48 Goldfine AB, Kahn CR. Adiponectin: linking the fat cell to insulin sensitivity. Lancet 2003; 362: 1431-1432
  • 49 Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599
  • 50 Asayama K, Hayashibe H, Dobashi K et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res 2003; 11: 1072-1079
  • 51 Togo T, Kojima K, Shoji M et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol 2004; 19: 37-40
  • 52 Han M, Deng C, Burne TH et al. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 2008; 33: 569-580
  • 53 Terry Jr AV, Warner SE, Vandenhuerk L et al. Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience 2008; 156: 1005-1016
  • 54 Kozlovskii VL, Kenunen OG, Khrabrova AV. Experimental study of the effects of citalopram, olanzapine, and their combinations in tests for antipsychotic, antidepressant and anxiolytic activities of drugs. Eksp Klin Farmakol 2008; 71: 6-10
  • 55 Ogilvie KM, Saladin R, Nagy TR et al. Activation of the retinoid X receptor suppresses appetite in the rat. Endocrinology 2004; 145: 565-573
  • 56 Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 2005; 353: 604-615
  • 57 Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116: 590-597
  • 58 Wolf G. Retinoic acid as cause of cell proliferation or cell growth inhibition depending on activation of one of two different nuclear receptors. Nutr Rev 2008; 66: 55-59
  • 59 Redonnet A, Ferrand C, Bairras C et al. Synergic effect of vitamin A and high-fat diet in adipose tissue development and nuclear receptor expression in young rats. Br J Nutr 2008; 100: 722-730
  • 60 Murano I, Morroni M, Zingaretti MC et al. Morphology of ferret subcutaneous adipose tissue after 6-month daily supplementation with oral beta-carotene. Biochim Biophys Acta 2005; 1740: 305-312
  • 61 Krupková M, Janků M, Liska F et al. Pharmacogenetic model of retinoic acid-induced dyslipidemia and insulin resistance. Pharmacogenomics 2009; 10: 1915-1927
  • 62 Bonet ML, Ribot J, Palou A. Lipid metabolism in mammalian tissues and its control by retinoic acid. Biochim Biophys Acta 2012; 1821: 177-189
  • 63 Bonet M-L, Ribot J, Felipe F et al. Vitamin A and the regulation of fat reserves. Cell Mol Life Sci 2003; 60: 1311-1321
  • 64 Tobita T, Takeshita A, Kitamura K et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans-retinoic acid. Blood 1997; 90: 967-973